CTC
BMRN icon

Central Trust Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Central Trust Company’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19
Closed -$1.04K – 1422
2025
Q2 		$1.04K Hold
19
– – ﹤0.01% 1365
2025
Q1 		$1.34K Sell
19
-42
-69% -$2.83K ﹤0.01% 1353
2024
Q4 		$4.01K Hold
61
– – ﹤0.01% 1233
2024
Q3 		$4.29K Sell
61
-97
-61% -$8.11K ﹤0.01% 1170
2024
Q2 		$13K Buy
158
+50
+46% +$4.16K ﹤0.01% 1019
2024
Q1 		$9.43K Buy
108
+32
+42% +$2.87K ﹤0.01% 1093
2023
Q4 		$7.33K Buy
76
+57
+300% +$5.04K ﹤0.01% 1111
2023
Q3 		$1.68K Buy
+19
New +$1.69K ﹤0.01% 1279
2022
Q3 		– Sell
-14
Closed -$1K – 1304
2022
Q2 		$1K Hold
14
– – ﹤0.01% 1268
2022
Q1 		$1K Buy
+14
New +$1.17K ﹤0.01% 1288
2020
Q3 		– Sell
-83
Closed -$10K – 1060
2020
Q2 		$10K Sell
83
-10
-11% -$994 ﹤0.01% 834
2020
Q1 		$8K Buy
+93
New +$8.01K ﹤0.01% 892
2017
Q2 		– Sell
-8
Closed – – 1244
2017
Q1 		$0 Buy
+8
New +$712 ﹤0.01% 1147

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Central Trust Company's BMRN Position: Q3 2025 in Review

Central Trust Company sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 19 shares — an estimated $1.04K sold.

Central Trust Company first reported a position in BMRN in Q1 2017 and held it in 13 quarters. The position peaked at $13K in Q2 2024. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Central Trust Company reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Central Trust Company sold 19 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $1.04K.
  • Central Trust Company first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 13 quarters.
  • Central Trust Company's BioMarin Pharmaceuticals position peaked at $13K in Q2 2024.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Central Trust Company's 13F filing for Q3 2025, filed 6 Nov 2025.